Effect of intensification of induction II chemotherapy and liberalization of stem cell donor source on outcome for children with high risk acute myeloid leukemia: A report from the Children’s Oncology Group.

Richard Aplenc,Lillian Sung,Jessica Pollard,Lisa Eidenschink Brodersen,Michael R. Loken,Robert B. Gerbing,Kelly D. Getz,Soheil Meshinchi,William G. Woods,E. Anders Kolb,Todd A. Alonzo,Alan S. Gamis

Effect of intensification of induction II chemotherapy and liberalization of stem cell donor source on outcome for children with high risk acute myeloid leukemia: A report from the Children’s Oncology Group.

2019

Richard Aplenc
Lillian Sung
Jessica Pollard
Lisa Eidenschink Brodersen
Michael R. Loken
Robert B. Gerbing
Kelly D. Getz
Soheil Meshinchi
William G. Woods
E. Anders Kolb
Todd A. Alonzo
Alan S. Gamis

10002Background: Patients with residual acute myeloid leukemia (AML) after induction fare poorly. The recently completed AAML1031 Phase III clinical trial intensified Induction II chemotherapy, alt...

Keywords:

Liberalization
Stem cell donor
Myeloid leukemia
Chemotherapy
Medicine
Oncology
Internal medicine
Clinical trial

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations